Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 1/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237618 | 0.82 | ALDH1A1 (0.45) | ALDH1A1TDP1TP53EDNRARXFP1 | |
| SCHEMBL6927887 | 0.79 | EDNRA (0.54) | ALDH1A1TDP1TP53EDNRARXFP1 | |
| SCHEMBL8648539 | 0.77 | PKM (0.50) | ALDH1A1TDP1TP53EDNRARXFP1 | |
| SCHEMBL30338563 | 0.77 | LMNA (0.57) | ALDH1A1TDP1TP53EDNRARXFP1 | |
| SCHEMBL634340 | 0.77 | LMNA (0.57) | ALDH1A1TDP1TP53EDNRARXFP1 | |
| SCHEMBL424725 | 0.76 | ALDH1A1 (0.50) | ALDH1A1EDNRAL3MBTL1SLC1A3SLC1A2 | |
| SCHEMBL426957 | 0.76 | PSEN1 (0.47) | ALDH1A1TDP1EDNRASLC22A12KAT6A | |
| SCHEMBL5346588 | 0.76 | HTR6 (0.51) | SLC22A12PKMKAT6ASLC40A1CA1 | |
| SCHEMBL7630639 | 0.75 | EDNRA (0.49) | ALDH1A1TDP1TP53EDNRARXFP1 | |
| SCHEMBL10530500 | 0.75 | ALDH1A1 (0.49) | ALDH1A1TDP1TP53EDNRARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169639-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | claimed |
| EP-3894402-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2021-10-20 | — | — | EP | claimed |
| CN-113286792-A | N-containing chromen-4-one derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-08-20 | — | — | CN | claimed |
| WO-2020120528-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | claimed |
| EP-2621902-B1 | 3-AZABICYCLO[3.1.0]HEXANE COMPOUNDS USEFUL FOR THE TREATMENT OF CNS DISORDERS | PANACEA BIOTEC LTD (IN) | 2017-04-12 | — | — | EP | claimed |
| EP-2621902-A2 | 3-AZABICYCLO [3.1.0] HEXANE COMPOUNDS USEFUL FOR THE TREATMENT OF CNS DISORDERS | Panacea Biotec Ltd. (IN) | 2013-08-07 | — | — | EP | claimed |
| WO-2012042539-A2 | NOVEL BICYCLIC COMPOUNDS | PANACEA BIOTEC LTD (IN) | 2012-04-05 | — | — | WO | claimed |
| EP-1170009-B1 | Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-04-07 | — | — | EP | claimed |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | UBE INDUSTRIES, LTD. (JP) | 2003-11-20 | — | — | US | claimed |
| EP-1254897-A1 | TRICYCLIC COMPOUNDS | Ube Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | claimed |
| EP-0685478-B1 | QUINOLINE DERIVATIVES | UBE INDUSTRIES (JP) | 2001-10-24 | — | — | EP | claimed |
| EP-0489547-B1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LTD (GB) | 1998-07-29 | — | — | EP | claimed |
| US-5591752-A | LEUKOTRIENE ANTAGONIST, ANTIALLERGEN, ANTIINFLAMMATORY AGENT, DIBENZ(B,E)OXEPINE | UBE INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | claimed |
| EP-0685478-A1 | QUINOLINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1995-12-06 | — | — | EP | claimed |
| EP-0489547-A1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | claimed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-0685478-A1 | QUINOLINE DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1995-12-06 | — | — | EP | disclosed |
| US-5280125-A | Chemical process for the preparation of 3-alkylated indole | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-01-18 | — | — | US | disclosed |
| EP-0489547-A1 | A process for the preparation of a 3-alkylated indole, intermediates, and a process for the preparation of a derivative thereof | ZENECA LIMITED (GB) | 1992-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169639-A1 | N-CONTAINING CHROMEN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, NR0B1, CYP7A1 | ALDH1A1 889/4885TDP1 1748/4885TP53 681/4885 |
| US-20030216571-A1 | Antiallergens; antiinflammatory agents | CYSLTR2, CYSLTR1, LTC4S | ALDH1A1 921/4885TDP1 3993/4885TP53 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.